SSR Index of Current-Quarter Healthcare Demand Growth: Initial 4Q13 Estimates

We expect 4Q13 health services demand growth (y/y, nominal) of 3.3%, the product of 2.2% growth in unit demand and 1.1% growth in nominal pricing (Exhibit 1). Our nominal pricing forecast is unchanged from last quarter’s multi-year low, while our estimate of y/y growth in unit demand is 20bps above 3Q13. Separate from our growth rate forecast, we run an independent model which handicaps the odds of a trend break in demand. This model calls for better than even odds (86%) of accelerating (4Q13 v. 3Q13) demand

 exh1

The pricing trend has been extremely weak since the 2% across the board cut in Medicare provider payments began on April 1 (Exhibit 2). Our modest 3Q13 forecast of 1.4% overestimated the actual y/y dynamics by 30bps. And, most notably, the trend has not really moderated since the April shock (Exhibit 3). The slight improvement in unit demand forecasts v. 3Q13 is a function of an improvement in the average wage momentum for health workers, which offset another dip in overall GDP growth forecasts in the Philadelphia Fed Survey of Professional Forecasters

exh2 exh3

Our estimates of demand dynamics for health services rely on several measures of underlying economic activity; included among these variables are measures of general economic activity and health-system specific activity, as well as forward expectations about US economic conditions

Exhibits 4, 5, and 6 provide time series of actual v. projected unit demand, price growth, and total demand, respectively

exh4 exh5 exh6

2013-2014 Flu Season

After the first 8 weeks of the 2013-14 flu season, this season now looks milder than the average (non-pandemic), season (Exhibit 7). Over the past decade, the majority of the variance in season severity can be explained by the severity at this point in the season – i.e., it’s not too early to say that the flu season now looks more likely to be closer to an average  year than to last year. An average 2013-14 flu season would translate into a +/- 30 bps headwind for total y/y health services demand growth during 4Q13

exh7

Richard Evans

Dr. Richard Evans, a 20 year industry veteran, leads SSR Health. As a senior executive in the pharmaceuticals industry, Dr. Evans responsibilities ranged from corporate strategy to the pricing and distribution of the company’s products. As an analyst with Sanford C. Bernstein, he was ranked #1 by both Bloomberg and Institutional Investor for his U.S. pharmaceuticals coverage – across all industries and coverage he was ranked one of the top 20 analysts worldwide. Dr. Evans is the author of “Health and Capital” published in August of 2009. He is a co-founder of SSR Health, LLC